Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: A pooled analysis of 13 clinical trials

European Journal of Haematology

Volumn 91, Issue 5, 2013, Pages 423-436

  Rodeghiero, Francesco ^a   Stasi, Roberto ^b   Giagounidis, Aristoteles ^c   Viallard, Jean François ^d   Godeau, Bertrand ^e   Pabinger, Ingrid ^f   Cines, Douglas ^g   Liebman, Howard ^h   Wang, Xuena ⁱ   Woodard, Paul ⁱ  

^a SAN BORTOLO HOSPITAL   (Italy)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c MARIEN HOSPITAL DÜSSELDORF   (Germany)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

Adverse events; Immune thrombocytopenia; Review; Romiplostim

Indexed keywords

PLACEBO; RETICULIN; ROMIPLOSTIM;

APLASTIC ANEMIA; ARTICLE; BLEEDING; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CATARACT; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FUNGEMIA; HEADACHE; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMATOLOGY; HEMOLYSIS; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LIVER FAILURE; LUNG CANCER; LUNG EMBOLISM; MULTIPLE MYELOMA; PNEUMONIA; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ADVERSE EVENTS; IMMUNE THROMBOCYTOPENIA; REVIEW; ROMIPLOSTIM;

ADULT; AGED; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RETICULIN; THROMBOPOIETIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 84885945807     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12181     Document Type: Article

References (60)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood 2009;113:2386-93.
2. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
3. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207.
4. Keating GM. Romiplostim: a review of its use in immune thrombocytopenia. Drugs 2012;72:415-35.
5. Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, Gleeson M, Danese M, Deuson R. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012;28:789-96.
6. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-99.
7. Stasi R, Murali M, Michel M, Viallard JF, Giagounidis A, Janssens A, Legg J, Deuson R, Danese MD. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. Int J Hematol 2012;96:26-33.
8. Janssens A, Tarantino MD, Bird R, et al. Final results from an international, multi-center, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts) 2011; 118: 3279.
9. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011;118:4338-45.
10. Rodeghiero F, Provan D, Cines D, Stasi R, Tarantino M, Nie K, Jun S. Safety analysis of long-term romiplostim use in patients with chronic immune thrombocytopenia (ITP). Haematologica 2010; 95(Suppl 2):73, abs. 0184
11. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81.
12. Newland A, Caulier MT, Schipperus MR, Kappers-Klunne M, Varet BR, Watkins K, Chen C-F, Nichol J. An open-label, unit dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (Pts) with immune thrombocytopenic purpura (ITP). Blood 2004;104:2058.
13. Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol 2009;90:157-65.
14. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011;118:28-36.
15. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
16. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 2011;94:71-80.
17. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161:411-23.
18. Shirasugi Y, Ando K, Miyazaki K, et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol 2012;95:652-9.
19. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia (ITP) patients treated with romiplostim. Blood 2009;114:3748-56.
20. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Erratum in: Blood. 2009;113:4822. Blood 2009;113:2161-71.
21. ® Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000942/WC500039537.pdf. Last accessed 11 May 2013.
22. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
23. Venna N, Gonzalez RG, Camelo-Piragua SI. Case records of the Massachusetts General Hospital. Case 11-2010. A 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging. N Engl J Med 2010;362:1431-7.
24. Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR. Health-related quality of life in non-splenectomised immune thrombocytopenia (ITP) patients receiving romiplostim or medical standard of care. Am J Hematol 2012;87:558-61.
25. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-42.
26. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54.
27. King H, Shumacker HB Jr. Splenic studies. I. Susceptibility to infection after splenectomy performed in infancy. Ann Surg 1952;136:239-42.
28. Schwartz PE, Sterioff S, Mucha P, Melton LJ 3rd, Offord KP. Postsplenectomy sepsis and mortality in adults. JAMA 1982;248:2279-83.
29. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182-6.
30. Ejstrud P, Kristensen B, Hansen JB, Madsen KM, Schonheyder HC, Sorensen HT. Risk and patterns of bacteraemia after splenectomy: a population-based study. Scand J Infect Dis 2000;32:521-5.
31. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861-8.
32. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, SØRensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010;8:1413-6.
33. Gernsheimer T, Kuter DJ, Cines DB, Stasi R, Rummel MJ, Godeau B, Guo M, Franklin J. Analysis of mortality rates during romiplostim clinical studies of patients (Pts) with immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts) 2010;116:3701.
34. Lam MS. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. J Oncol Pharm Pract 2010;16:89-103.
35. Cuker A, Chiang EY, Cines DB. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf 2010;5:171-81.
36. Catala-Lopez F, Corrales I, Martin-Serrano G, Tobias A, Calvo G. Risk of thromboembolism treated with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc) 2012;139:421-9.
37. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004;76:205-13.
38. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379:244-9.
39. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95:1167-75.
40. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, Sørensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011;152:360-2.
41. Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol 2010;92:289-95.
42. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2005;84:411-5.
43. Ruggeri M. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective. Am J Hematol 2012;87:946-7.
44. Altomare I, Wasser J, Pullarkat V. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. Am J Hematol 2012;87:984-7.
45. Arnold DM. Platelet count or bleeding as the outcome in ITP trials? Am J Hematol 2012;87:945-6.
46. Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013;121:2596-606.
47. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011; Art. No.: CD008235.
48. Michel M, te Boekhorst PA, Janssens A, Pabinger-Fasching I, Sanz MA, Nie K, Kreuzbauer G. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology 2011;16:274-7.
49. Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH Jr, de Wolf JT, Stewart R, Berger D. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). Am J Hematol 2009;84:538-40.
50. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010;8:1372-82.
51. Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol 1971;56:24-31.
52. Beckman EN, Brown AW Jr. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med 1990;114:1241-3.
53. Mufti G, Bagg A, Hasserjian R, Bain B, Kuter D, Dreiling L, Nichol J. Bone marrow reticulin in patients with immune thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts) 2006;108:3982.
54. Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol 2012;25:65-74.
55. Saleh MN, Bussel JB, Meyer O, Frederiksen H, Johnni D, Aivado M, Brainsky A. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag. Blood (ASH Annual Meeting Abstracts) 2009;114:1326.
56. Brynes RK, Orazi A, Verma S, Brainsky A, Bailey CK, Bakshi K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag - data from the EXTEND study. Blood (ASH Annual Meeting Abstracts) 2011;118:528.
57. Rodeghiero F, George JN, Rummel M, Anderson D, Chong BH, Boda Z, Hellmann A, Wang X, Woodard P. Results from a phase IV open-label study evaluating changes in bone marrow morphology in adult immune thrombocytopenia (ITP) patients receiving romiplostim: analysis of the 1-year romiplostim cohort. Haematologica (EHA Meeting Abstracts) 2012;97(s1):425.
58. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8.
59. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
60. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47.